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BTCPAbstract Aim: To compare bone regeneration in noncritical rat calvarial bone defects ﬁlled with
platelet-rich ﬁbrin (PRF), alone or combined with beta-tricalcium phosphate (b-TCP), using micro-
computed tomographic (MCT) evaluation.
Animals and methods: Two calvarial bone defects were created in each of 45 male Sprague–Daw-
ley rats (age: 20–22 weeks, weight: 350–450 g), using a dental trephine with an external diameter of
3 mm. The 90 defects were randomly allocated among three groups, each containing 30 unilateral
defects in a total of 30 rats. Defects in the control group were allowed to heal spontaneously.
Defects in the PRF group received PRF alone. Defects in the PRF/b-TCP group received PRF
mixed with b-TCP in a 50n50 percentage. Nine animals (three per group) were killed after 1, 2,
3, 4, and 6 postoperative weeks, and 18 calvarial defects from each period were analyzed for new
bone formation and bone mineral density using MCT. Results were compared by a one-way Anal-
ysis of Variance with the POST HOC Least Signiﬁcant Difference test.
Results: The volume and mineral density of bone formed in the control group were signiﬁcantly
different from those of the other two groups. Greater bone regeneration was observed in defects
receiving PRF with b-TCP compared to defects receiving PRF alone in the ﬁrst 2 weeks
(P< 0.001). However, differences in the volume and density of newly formed bone between the
PRF and PRF/b-TCP groups were not signiﬁcant at 3, 4, and 6 postoperative weeks (P > 0.005).
110 W.A. AbdullahConclusion: The addition of b-TCP to PRF signiﬁcantly improved bone regeneration in the ﬁrst
2 weeks after surgery. Although the differences between results with and without the addition of
b-TCP to PRF were statistically insigniﬁcant from weeks 3 to 6, it was nevertheless apparent that
the group receiving the combination showed better results. We suggest a synergistic mechanism for
this effect.
 2016 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Various growth factors are increasingly being used – either
alone or together with bone graft materials – in dental and
medical applications, especially in maxillofacial surgery for
bone augmentation and regeneration. Among these factors
are platelet-rich plasma (PRP) and platelet-rich ﬁbrin (PRF)
(Yilmaz et al., 2014). PRP has been found to improve bone
regeneration due to its high concentration of bioactive proteins
(Zimmermann et al., 2001; Zhang et al., 2012). However, stud-
ies of the effects of PRP on new bone formation in experimen-
tal and human subjects have found inconsistent results
(Wiltfang et al., 2003; Gerard et al., 2006, 2007; Kazakos
et al., 2011; Zhang et al., 2012). Some authors have attributed
this inconsistency to the extremely short-term effects of grafted
PRP, due to the rapidly decreasing concentration of bioactive
proteins (Schmitz and Hollinger, 2001; Marx, 2004).
Choukroun’s PRF is a recently developed second-
generation platelet concentrate, which is prepared through a
simple method that does not require the addition of chemicals
to blood samples before centrifugation. The end product is an
autologous ﬁbrin matrix containing platelets and leukocyte
growth factors, which are obtained from inside the ﬁbrin clot,
which may explain the slow release of bioactive proteins
(growth factors) from the PRF (Dohan et al., 2006; Dohan
Ehrenfest et al., 2009; Zhang et al., 2012). The platelet (throm-
bocyte) count in PRF is three-to-seven times greater than its
normal concentration in blood. Growth factors obtained from
PRF include platelet-derived growth factor (PDGF), trans-
forming growth factor (TGF), and insulin-like growth factor
(Marx, 2001; Dohan Ehrenfest et al., 2009).
Several clinical studies and case reports have referred to
PRF as a promising biomaterial that can be used alone or in
combination with other bone graft materials to accelerate bone
regeneration (Lee et al., 2012; Mazor et al., 2009; Magremanne
et al., 2009; Choukroun et al., 2006). However, studies of
the potential synergistic effects of PRF when used in combina-
tion with different bone graft materials have found inconsis-
tent results, possibly due to the different bioactive properties
of graft materials (Choukroun et al., 2006; Zhang et al., 2012).
Histologic, radiographic, and mechanical analytical meth-
ods are available for evaluating the volume and quality of
newly formed regenerated bone. For example, advances in
radiographic analysis, such as micro-computed tomography
(MCT), allow for the three-dimensional reconstruction and
measurements of the bone volume (BV) and bone mineral
density (BD) of newly formed bone in the study defect
(Spicer et al., 2012). Animal models of bone defect healing
have been developed in many species, including mice, rats, rab-
bits, dogs, pigs, sheep, and goats. Much research has focused
on rodent models, however, because of their reproducibilityand economic considerations (Spicer et al., 2012; Pearce
et al., 2007). The generally accepted critical size for calvarial
defects is 8 mm, although smaller defects have been used, with
a pattern of two defects per animal. This approach allows
fewer animals to be killed (Kim et al., 2010; Spicer et al., 2012).
To the best of our knowledge, there have been no clear
reports of the application of PRF combined with beta-
tricalcium phosphate (b-TCP) in intramembranous bone, the
main type of cranio-maxillo-facial bone. Therefore, the aim
of the present study was to use histological and MCT evalua-
tions to compare new bone regeneration in noncritical rat
calvarial bone defects ﬁlled with either PRF alone or a PRF/
b-TCP combination.
2. Materials and methods
This study was approved by the College of Dentistry Research
Center, King Saud University, Saudi Arabia, duly governed by
its ‘‘Ethical Consideration for Animals” document, in confor-
mity with National Institute of Health guidelines for the care
and use of laboratory animals (NIH Publication #85-23 Rev.
1985). Forty-ﬁve 20- to 22-week-old male Sprague–Dawley
rats (weight: 350–450 g) were used. Rats were individually
housed in metallic cages with ease of access to water and food
in the Laboratory Animal Center of King Khalid University
Hospital, King Saud University, Saudi Arabia, under veteri-
nary supervision.
Rats were anesthetized by intramuscular injection of xyla-
zine (5 mg/kg; Lloyd Laboratories, Shenandoah, IA, USA)
and ketamine (20 mg/kg; Sigma–Aldrich, St. Louis, MO,
USA). The surgical area was shaved from the bridge of the
snout between the eyes to the caudal end of the skull/calvar-
ium. After shaving, an alcohol swab was used to remove hair
trimmings, and the area was disinfected with a 10% povi-
done–iodine solution (Riyadh Pharma, Riyadh, Saudi Arabia)
the surgical procedure is illustrated in Fig. 1. The subcuta-
neous area of the surgical ﬁeld was injected with half a car-
tridge of 1.8 mL of 2% lidocaine (Parhawk Laboratories,
Inc., Lenexa, KS, USA). An approximately 1.5-cm incision
was created, using a #15 blade, down to the periosteum over
the scalp from the nasal bone to the caudal of the middle sagit-
tal crest or bregma. The periosteum was sharply incised down
the sagittal midline with the same scalpel. Finally, the perios-
teum was elevated from the cranial bone laterally with a
mucoperiosteal elevator.
A 4-mL blood sample was obtained from the orbital sinus
of each rat. The blood sample was collected in a plain tube,
which was immediately centrifuged at 3000 rpm for 12 min
to prepare the PRF.
While blood samples were being centrifuged, two noncriti-
cally sized (3-mm diameter) bone defects were created, with
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Figure 1 Clinical intraoperative photographs showing the following; A: incision, B: the bilateral claverial surgical defect, C: PRF inside
the glass tube after its preparation (black arrow), D: PRF grasped with a tissue forceps after its separation from the remaining blood clot
and components, E: ﬁlling one claverial defect with PRF/BTCP (blue arrow) and ﬁlling the other one with PRF alone (green arrow),
F: closure of the periosteum using 3/0 vicryl.
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lowed the protocol of Spicer et al. (2012) for creation of the
calvarial defects. Brieﬂy, a dental trephine (Stoma Trephine
Bur, 2–3 mm (2 mm inner diameter and 3 mm outer diameter),
Dental Latch, Ref: 22349.02; Swallow Dental Supplies Ltd.,
Silsden, Keighley, West Yorkshire, UK) was used against the
superﬁcial aspect of the calvarium, together with a low-speed
(1000 rpm) surgical drill under copious saline irrigation. Inter-
nal and external diameters of the trephine were 2 and 3 mm,
respectively. The bone was not completely penetrated by the
trephine to avoid damaging the underlying dural and brain tis-
sues. As the calvarium at the circular border of the defect
thinned and became translucent, gentle pressure was exerted
with the tip of a small elevator around the inner portion of
the defect margins. Then, the trephinated portion of bone
was partially displaced downward with slight pressure on one
side of the circle. The elevator was used to gently dissect and
separate the bone segment from the dura (Fig. 1). The two bone
defects were irrigated thoroughly with normal saline.
The 90 defects were randomly allocated among three
groups, each containing 30 unilateral defects in a total of 30
rats. In the control group, defects were allowed to heal sponta-
neously. In the PRF group, defects were treated with PRF. In
the PRF/b-TCP group, defects were treated with equal vol-
umes (50n50) of PRF mixed with b-TCP (Kasios TCF; Lau-
naguet, France; particle size: 1000–2000 lm). The periosteum
was sutured using 4–0 vicryl suture material, and the surgical
site was closed -using 4–0 black silk (Futura Surgicare Pvt.
Ltd., Bangalore, India) (Fig. 1).
On the day of surgery, rats were intramuscularly injected
twice with the antibiotic amikacin (5 mg/lb). The ﬁrst injection
was given immediately before the surgery and the second onewas injected 12 h after the ﬁrst injection. Rats were given oral
amoxicillin (10 mg/lb) twice daily for 5 days, and the anti-
inﬂammatory agent meloxicam (0.5 mg/kg) orally for 3 days.
2.1. MCT analysis of bone defects
At ﬁve time points (1, 2, 3, 4, and 6 weeks after surgery), three
rats were randomly selected from each group and killed, for a
total of nine rats (18 calvarial defects) per period. The calvarial
bone of each rat was dissected, ﬁxed in 10% formaldehyde,
and wrapped in paraﬁlm (Brand GmbH, Germany) to prevent
drying during scanning. Specimens were scanned with a high-
resolution in vivo X-ray MCT instrument (SkyScan 1176,
Kontich, Belgium) with an aluminum ﬁlter (1 mm). Scan set-
tings were as follows: energy of 100 kV, intensity of 343 mA,
resolution of 12.39 lm pixels, rotation step size of 0.6, tomo-
graphic rotation of 1800 (1800 projection images were
acquired by a tomographic scan over 180-degree sample rota-
tion), and standard camera setting (ﬁeld width = 1000 pixels).
Projection images of cone-beam acquisition and reconstruction
were saved as 16-bit TIF ﬁles. All scanning and reconstruction
parameters were identical for all specimens and calibrations.
We analyzed the MCT scans of specimens using the NRe-
con reconstruction software, Data Viewer software, and CT-
Analyzer program (BRUKER- MICROCT Kontich, Belgium)
in a control computer (Windows 7, 64-bit version). Parameters
acquired via MCT were the BV (mm3) and BD (mg/cm3) of
mineralized tissue within the circular defect area (region of
interest, ROI). As a quantitative indicator of newly formed
mineralized tissue, BV was deﬁned as the volume of mineral-
ized tissue formed at the defect site during healing. As an indi-
cator of the quality of mineralized tissue, BD was deﬁned as
112 W.A. Abdullahthe density of mineralized tissue within the volume of interest
(Nooh et al., 2014).
ROIs for BV were identiﬁed using the previously mentioned
CT analyzer program. The area of newly formed bone was
measured in each section of the MCT scan. The product of
the measured area and the slice thickness of the scan section
yielded the BV in that scan section. The sum of the BV values
of each scan section was calculated to determine the total BV
of newly formed bone.
To calculate the BD of newly formed bone, four represen-
tative sites were selected from each specimen. Each site was
selected to represent either the superior or inferior aspect of
the proximal and distal portions of the bone cavities, 1 mm
from the edges. The mean of the individual BD values
obtained from each site was calculated to obtain the total
BD of newly formed bone.
2.2. Statistical analysis
Assuming a type 1 error value of 5% (a= 0.05) and power of
0.95, we estimated that we would need a sample size of 90PRF/BTCP PRF
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Figure 2 Micro-computed tomography sections of the rat claverial b
reconstruction of the defects (B) axial reconstruction of the defects. Ol
purple.defects (n = 18/group) distributed evenly among three groups
during ﬁve examination periods. BV and BD values of the
three groups were compared by a one-way Analysis of Vari-
ance (ANOVA), followed by the post hoc Least Signiﬁcant
Difference (LSD) test. The factor for ANOVA was the grafted
material in the defects (PRF, PRF/b-TCP, or control).
P< 0.05 was considered to be statistically signiﬁcant. All
statistical analyses were performed using SPSS for Windows,
version 21 (SPSS, Chicago, IL, USA).
3. Results
All 45 rats showed an uneventful recovery from the anesthesia and sur-
gical procedures. All 90 standardized calvarial bone defects were
included in the ﬁnal analysis. There were no signs of infection, hema-
toma, or wound dehiscence during the wound healing period. No
behavioral changes or signs of paralysis were noted throughout the
study period.
Examination of the specimens after the ﬁrst postoperative week
revealed much smaller volumes of newly formed bone in defects from
the control group (n = 6) compared to defects in the PRF group
(n = 6) or PRF/b-TCP group (n = 6). The PRF/b-TCP group showedCONTROL
one showing the three groups all over the study period (A) coronal
d bone was colored with yellow color, while the new bone colored
Table 1 Showing mean value and slandered deviation of bone volume and bone mineral density in all groups.
Examination Periods in weeks Group (n= 6) Mean ± SD
Bone volume (mm3) Bone density (mg/cm3)
1 Control 2.079 ± 0.27 0.4355 ± 0.047633
PRF 5.694 ± 1.028741 0.5815 ± 0.02362
PRF+BTCP 8.834167 ± 0.284476 0.6585 ± 0.03084
2 Control 3.172 ± 0.48 0.510333 ± 0.012023
PRF 7.567 ± 0.983494 0.6145 ± 0.018945
PRF+BTCP 10.83317 ± 0.146576 0.826667 ± 0.038668
3 Control 6.733 ± 0.92 0.602667 ± 0.004853
PRF 12.501 ± 1.400921 0.9095 ± 0.03517
PRF+BTCP 12.6145 ± 0.172101 0.9245 ± 0.043481
4 Control 7.608 ± 0.98 0.625 ± 0.038575
PRF 14.214 ± 0.348846 0.9415 ± 0.033385
PRF+BTCP 14.32335 ± 0.693714 0.960167 ± 0.044823
6 Control 8.429 ± 1.40 0.641333 ± 0.034855
PRF 14.845 ± 0.439037 0.991 ± 0.008602
PRF+BTCP 14.86883 ± 0.104396 0.9955 ± 0.002986
SD= Standard deviation.
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Table 1). After the second postoperative week, the control group spec-
imens showed only a slight increase in the volume of newly formed
bone, which was still less than the volumes that had formed after just
1 week in the other two groups. Moreover, the volumes of newly
formed bone in the PRF and PRF/b-TCP groups were increased con-
siderably at 2 weeks compared to the volumes at 1 week. The BV in
defects of the PRF/b-TCP group remained greater than the BV in
the PRF group (Figs. 2 and 3, Table 1).
After 3, 4, and 6 weeks, all specimens continued to show much
smaller volumes of newly formed bone in the control group compared
to the other two groups. However, in contrast to the ﬁrst two periods,
the volumes of newly formed bone were very similar in the PRF and
PRF/b-TCP groups in these examination periods (Figs. 2 and 3,
Table 1).
3.1. Statistical results
One-way ANOVA with the LSD test for BV and BD revealed signiﬁ-
cant differences between the control group and the other two groups.
The BV and BD values of the PRF/b-TCP group were signiﬁcantly
greater than those of the PRF group in weeks 1 and 2 (P< 0.001).0 
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Figure 3 Clustered column chart with error bars showing bone
volume (BV) in the 3 groups all over the study period.However, these differences were not signiﬁcant for weeks 3, 4, or 6
(P> 0.05) (Figs. 2 and 3, Tables 2 and 3).
4. Discussion
The present study investigated the effect of PRF, either alone
or in combination with b-TCP, on bone healing in standard-
ized rat calvarial bone defects. Newly formed bone was evalu-
ated by MCT analysis of the BV and BD values.
Rat calvarial bone defects have been considered a rapid-
throughput method for the evaluation of bone regeneration.
Rat calvarium allows for a reproducible defect that does not
need ﬁxation, as a result of the reduced loading compared to
loading in long bones. Calvarial defects can also be used as a
model for intramembranous bone formation (Spicer et al.,
2012; Pearce et al., 2007; Schmitz and Hollinger, 1986;
Takagi and Urist, 1982; Wang et al., 2003).
Our MCT results revealed that the quantity (BV) and den-
sity (BD) of newly formed bone were signiﬁcantly different
among the three groups in the ﬁrst two postoperative weeks.
The best results were obtained for defects ﬁlled with the
PRF/b-TCP combination, followed by PRF alone and then
the control group. These results are consistent with those of
Yilmaz et al. (2014), who found that adding b-TCP to PRF
improved the efﬁcacy of bone formation compared to using
either material alone. In another study, Lee et al. (2007) com-
pared autogenous grafts to autogenous graft+PRF combina-
tions for sinus-lifting operations. Based on a
histomorphometric analysis, they found a greater amount of
bone in the autogenous graft+PRF combination group com-
pared to the group treated with autogenous bone grafts alone
(see Fig. 4).
Chazono et al. (2004) and Shirasu et al. (2010) proposed an
explanation for the increased bone formation and osteoblast
proliferation in the presence of b-TCP. They reported that
osteoclastic cells surrounding bone graft particles play a role
in the induction of osteoblastic cell migration around bone
graft particles of b-TCP by cell-to-cell interactions. These
Table 2 Showing the results of a one-way ANOVA posthoc statistical analysis of all groups regarding bone volume.
Examination periods in weeks Group Mean diﬀerence (I–J) P value
I J
1 Control PRF 3.614833* .000
PRF+BTCP 6.754833* .000
PRF Control 3.614833* .000
PRF+BTCP 3.140000* .000
PRF+ BTCP Control 6.754833* .000
PRF 3.140000* .000
2 Control PRF 4.394667* .000
PRF+BTCP 7.660333* .000
PRF Control 4.394667* .000
PRF+BTCP 3.265667* .000
PRF+BTCP Control 7.660333* .000
PRF 3.265667* .000
3 Control PRF 5.767500* .000
PRF+BTCP 5.881000* .000
PRF Control 5.767500* .000
PRF+BTCP .113500 .856
PRF+BTCP Control 5.881000* .000
PRF .113500 .856
4 Control PRF 6.606000* .000
PRF+BTCP 6.715017* .000
PRF Control 6.606000* .000
PRF+BTCP .109017 .814
PRF+BTCP Control 6.715017* .000
PRF .109017 .814
6 Control PRF 6.415167* .000
PRF+BTCP 6.439000* .000
PRF Control 6.415167* .000
PRF+BTCP .023833 .965
PRF+BTCP Control 6.439000* .000
PRF .023833 .965
* The mean difference is signiﬁcant at the 0.05 level.
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who found that a group receiving PRF mixed with b-TCP
showed a larger bone formation area compared to the negative
control group and the TCP-alone group.
From the third to the sixth postoperative week, we
observed a change in the previous pattern of the ﬁrst two
weeks. Although the PRF/b-TCP group still exhibited a
greater improvement in BV and BD compared to the PRF
group, this difference was no longer signiﬁcant. This ﬁnding
contradicts the results of Yilmaz et al. (2014), who found that
the amount of bone was signiﬁcantly different between the
PRF/b-TCP group and the PRF-alone group throughout the
study period. Nevertheless, the PRF/b-TCP and PRF groups
continued to show highly signiﬁcant differences in BV and
BD compared to the control group.
To explain the ﬁndings in the ﬁrst 14 days of the present
study, we refer to similar results from He et al. (2009), which
compared the utility of PRF with PRP in osteoblast prolifera-
tion. When PRF was used, the levels of released TGF-b1 and
PDGF-AB were markedly increased, peaking on day 14 before
decreasing slightly. From these results, we can hypothesize that
the difference between the PRF/b-TCP and PRF groups in the
ﬁrst 2 weeks had two causes: the bone formation-stimulatory
activity of the b-TCP itself (Szabo et al., 2001), and thesustained and gradual increase of growth factor release by
PRF. The PRF acts as a biological ‘‘glue” to hold the particles
together, enabling manipulation of the bone grafting material
and holding the graft material in the defect area. Yazawa et al.
(2004) and Yilmaz et al. (2014) concluded that this adhesive
property had the synergetic effect of accelerating healing of
the graft material. After the maximum promoting effect of
PRF occurred at day 14, the release of the growth factors
started to decrease. Although the presence of b-TCP in combi-
nation with PRF still afforded an improvement in bone forma-
tion and mineral density over PRF alone, this effect was no
longer signiﬁcant.
Another explanation for the increased bone formation in
the PRF/b-TCP group may be the dissolution of b-TCP after
grafting. Wang et al. (1998) and Jarcho (1981) suggested that
the dissolution of TCP may provide high local concentrations
of calcium and phosphate, providing a favorable environment
for new bone formation. Conversely, Shirasu et al. (2010)
argued that, because calvarial bone has relatively little bone
marrow, the number of osteoprogenitor cells at the recipient
site is minimal. Thus, for full-thickness defects of intramem-
branous calvarial bone, b-TCP grafting alone may be insufﬁ-
cient for successful osteoconduction. This fact emphasizes
the synergetic effect of the presence of PRF with b-TCP in
Table 3 Showing a one-way ANOVA posthoc statistical analysis of all groups regarding the bone mineral density.
Examination periods in weeks Group Mean diﬀerence (I–J) P value
I J
1 Control PRF .1460000* .000
PRF+BTCP .2230000* .000
PRF Control .1460000* .000
PRF+BTCP .0770000* .004
PRF+BTCP Control .2230000* .000
PRF .770000* .004
2 Control PRF .1041667* .000
PRF+BTCP .3163333* .000
PRF Control .1041667* .000
PRF+BTCP .2121667* .000
PRF+BTCP Control .3163333* .000
PRF .2121667* .000
3 Control PRF .3068333* .000
PRF+BTCP .3218333* .000
PRF Control .3068333* .000
PRF+BTCP .0150000 .476
PRF+BTCP Control .3218333* .000
PRF .0150000 .476
4 Control PRF .3165000* .000
PRF+BTCP .3351667* .000
PRF Control .3165000* .000
PRF+BTCP .0186667 .463
PRF+BTCP Control .3351667* .000
PRF .0186667 .463
6 Control PRF .3496667* .000
PRF+BTCP .3541667* .000
PRF Control .3496667* .000
PRF+BTCP .0045000 .737
PRF+BTCP Control .3541667* .000
PRF .0045000 .737
* Signiﬁcant difference P  0.05.
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duction process.
Lundquist et al. (2008) and He et al. (2009) stated that col-
lagen synthesis creates an extracellular matrix for osteoblasts,
which can be used as a skeleton for the deposition of calcium
nodules. PRF released the maximum amount of TGF-b1
(which enhances collagen synthesis, possibly through connec-0 
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Figure 4 Clustered column chart with error bars showing bone
mineral density (BMD) in the 3 groups all over the study period.tive tissue growth factor (CTGF), another platelet-derived
protein) at 14 days, which may have led to maximum mineral-
ization during this period. According to Uggeri et al. (2007),
the ﬁbrin(ogen) content of PRFs may also contribute to their
increased mineralization. The lack of a signiﬁcant difference
in our MCT measurements of BV and BD between the PRF/
b-TCP and PRF groups may have been affected by the
MCT computer program, which we used to subtract from
those calculations the b-TCP particles that showed in the
MCT cuts. Finally, slow resorption may have retarded the for-
mation of new bone. And this did not affect the PRF group
because in the prf group there is no particle at all.
Researchers have explored the potential synergistic effects
of PRF combined with various bone graft materials. However,
such studies have obtained widely varying results, possibly due
to the different bioactive properties of the graft materials
(Choukroun et al., 2006; Zhang et al., 2012; Yilmaz et al.,
2014; Yazawa et al., 2004; Szabo et al., 2001).
5. Conclusions
The study found improved bone regenerative capacity of
defects treated with PRF in combination with b-TCP, com-
pared to defects treated with PRF alone. However, the effect
116 W.A. Abdullahwas only statistically signiﬁcant in the ﬁrst 2 weeks after sur-
gery. Nevertheless, it was apparent that the group receiving
the combination displayed greater bone regeneration. This
study has some limitations, and further studies are necessary
to strengthen the evidence base and to explore the possible syn-
ergistic mechanism of this treatment in intramembranous
bone.
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